Jim Lang Joins Halozyme Therapeutics as a New Board Member

Jim Lang Joins Halozyme's Board of Directors

Halozyme Therapeutics, Inc. has recently announced the election of Jim Lang to its Board of Directors, marking a significant step forward for the company. With an impressive background spanning over three decades in healthcare, life sciences, business services, and data analytics, Lang is poised to be a pivotal addition to the team.

Dr. Helen Torley, President and CEO of Halozyme, expressed enthusiasm about Lang’s election, stating, "Jim brings extensive experience in building and scaling innovative healthcare businesses, and we are delighted to welcome him to the Halozyme board." She emphasized that his strategic insight and ability to drive growth—particularly through mergers and acquisitions—will be invaluable as Halozyme continues to implement its growth strategy and create significant value for stakeholders, including partners, patients, and shareholders.

A Track Record of Success

Before joining Halozyme, Lang served as the Chief Executive Officer of EVERSANA, a leading global provider of commercialization services in the life sciences sector. Under his leadership, EVERSANA achieved remarkable growth by acquiring over twenty companies and culminating in its merger with Waltz Health in August 2025. He remains a board member at EVERSANA, leveraging his extensive experience in navigating complex business environments.

Previously, Lang was the CEO of Decision Resources Group (DRG), where he played a crucial role in transforming the data analytics firm into a market leader through significant expansions and acquisitions. His career also includes a position as President of Strategic Decision Group, where he advanced the life sciences practice before selling it to IMS Health, now known as IQVIA.

In addition to his role at Halozyme, he currently serves on the board of Biovie, Inc., a clinical-stage biopharmaceutical company, where he chairs the Audit Committee as well as the Nominating and Corporate Governance Committee. He is also a board member of OptimizeRx Corporation, a digital healthcare technology firm, where he chairs the Compensation Committee.

Vision for Halozyme

Lang expressed his gratitude upon being elected to the Board, saying, "I am honored to join Halozyme's Board of Directors. Halozyme has a strong foundation and a compelling strategy for growth. I look forward to working with the leadership team to help accelerate that growth and deliver even greater value to our shareholders."

Holding a Bachelor of Science degree in Electrical and Computer Engineering from the University of New Hampshire and an MBA from the Tuck School of Business at Dartmouth, Lang combines technical expertise with business acumen, positioning him well for his new role.

About Halozyme

Halozyme Therapeutics specializes in developing innovative solutions that enhance patient experiences and outcomes with both emerging and established therapies. The company is known for its ENHANZE® drug delivery technology, featuring the proprietary enzyme rHuPH20, which enables the subcutaneous delivery of injected treatments, thereby reducing the burden on patients and improving convenience.

Since its introduction, the ENHANZE® technology has positively impacted over one million patients worldwide and is included in ten commercialized products across more than 100 global markets. Halozyme's technology has been licensed by top pharmaceutical and biotechnology firms, including Roche, Pfizer, Takeda, AbbVie, and Bristol-Myers Squibb, indicating widespread recognition and trust in its efficacy.

In addition to ENHANZE®, Halozyme is advancing its portfolio with the development of Hypercon™, an innovative microparticle technology aimed at revolutionizing drug concentration delivery. This new technology is expected to set a new industry standard, enabling lower injection volumes while expanding therapy delivery options for healthcare providers and patients alike.

Halozyme has additional commercial products, including Hylenex® and XYOSTED®, and continues its collaborative efforts with prominent partners like Teva Pharmaceuticals and McDermott Laboratories, reaffirming its commitment to transforming the patient treatment experience.

Headquartered in San Diego, CA, with operations in Ewing, NJ, Minnetonka, MN, and Boston, MA, Halozyme is well-positioned for ongoing innovation in biopharmaceuticals. For more information about their offerings and initiatives, visit Halozyme's website and follow their updates on LinkedIn and Twitter.

Forward-Looking Statements

This press release may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Halozyme undertakes no obligation to update any forward-looking statements.

For inquiries, please contact:

Tram Bui
VP, Investor Relations
Halozyme Therapeutics, Inc.
609-359-3016
[email protected]